Posts

Physicists ‘entangle’ individual molecules for the firs...

For the first time, a team of Princeton physicists have been able to link togeth...

Seattle Hub for Synthetic Biology launched by Allen Ins...

The Allen Institute, the Chan Zuckerberg Initiative (CZI), and the University of...

Virtualware and Kessler Foundation renew collaboration ...

East Hanover, NJ – December 07, 2023 – Kessler Foundation, a leader in rehabilit...

The evolutionary paradox behind the unusual mating stra...

In the colorful world of avian courtship, the ruff (Calidris pugnax) is in a lea...

JMIR Mental Health call for papers theme issue on Affec...

JMIR Mental Health, a premier SCIE/PubMed/Scopus-indexed, peer-reviewed journal ...

Discrimination during pregnancy may alter circuits in i...

Racial discrimination and bias are painful realities and increasingly recognized...

Study: How farmers decide to store or sell their grain

URBANA, Ill. – When farmers harvest their grain, they can choose to sell it righ...

UTA to train interdisciplinary researchers in mathemati...

The National Science Foundation (NSF) has awarded The University of Texas at Arl...

Virtual reality simulations can help autistic people co...

COLUMBIA, Mo. — Many people associate virtual reality headsets with interactive ...

SLAC brings rapid-fire laser and target expertise to na...

The U.S. Department of Energy’s SLAC National Accelerator Laboratory and Stanfor...

Microscopic “super bots” repair neural wound model

In a recent development, scientists have brought science fiction to life by crea...

Lilly’s Jaypirca leads the leukemia trail with FDA appr...

In the highly competitive landscape of BTK inhibitors for blood cancer treatment...

Merus Faces Setback Following Interim Report for Lung C...

Merus, a biopharmaceutical company, confronted a significant setback following a...

Merck’s Evobrutinib Encounters Setbacks in MS Trials Am...

Merck KGaA’s foray into the competitive BTK inhibitor space has hit a roadblock,...

LY-3885125 by Eli Lilly and Co for Dyslipidemia: Likeli...

LY-3885125 is under clinical development by Eli Lilly and Co and currently in Ph...

Tislelizumab by BeiGene for Gastric Cancer: Likelihood ...

Tislelizumab is under clinical development by BeiGene and currently in Phase III...